Literature DB >> 3281462

Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections.

D L Hemsell1, G D Wendel, S A Gall, E R Newton, R S Gibbs, R A Knuppel, T W Lane, R L Sweet.   

Abstract

Two hundred eighty-seven women were treated in a multicenter, randomized, comparative study to compare the safety and efficacy of cefotetan every 12 hours with that of cefoxitin every 6 or 8 hours in the treatment of acute obstetric and gynecologic pelvic infections. The most frequent primary diagnoses in both groups were endometritis and pelvic inflammatory disease; 24 of these patients were also bacteremic. The mean duration of treatment was 5.2 and 5.4 days for the cefotetan and cefoxitin groups, respectively, and the total doses administered were 18.1 and 32.1 gm, respectively. The rate of clinical failure for the cefotetan group was 8.5% and 12.2% for the cefoxitin group. Laboratory and clinical adverse reactions were infrequent and none was serious; both antimicrobials were well tolerated. These results suggest the administration of cefotetan provided adequate clinical and bacteriologic effectiveness in the treatment of hospital- and community-acquired, polymicrobial obstetric and gynecologic pelvic infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281462     DOI: 10.1016/s0002-9378(16)44535-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

Review 2.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 3.  Antibiotic regimens for postpartum endometritis.

Authors:  A Dhanya Mackeen; Roger E Packard; Erika Ota; Linda Speer
Journal:  Cochrane Database Syst Rev       Date:  2015-02-02

4.  Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors:  M J Gribble
Journal:  CMAJ       Date:  1994-09-01       Impact factor: 8.262

5.  Antibiotic therapy for pelvic inflammatory disease.

Authors:  Ricardo F Savaris; Daniele G Fuhrich; Jackson Maissiat; Rui V Duarte; Jonathan Ross
Journal:  Cochrane Database Syst Rev       Date:  2020-08-20

6.  Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.

Authors:  Subir Roy; Iliana Higareda; Edith Angel-Muller; Mahmoud Ismail; Caren Hague; Ben Adeyi; Gail L Woods; Hedy Teppler
Journal:  Infect Dis Obstet Gynecol       Date:  2003

7.  Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin.

Authors:  D L Hemsell; G D Wendel; P G Hemsell; M L Heard; B J Nobles
Journal:  Infect Dis Obstet Gynecol       Date:  1993
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.